Publication Name	World Journal of Clinical Cases
Manuscript ID	92018
Country	China

Received	2024-01-12 14:48
Peer-Review Started	2024-01-12 14:48
First Decision by Editorial Office Director	2024-01-31 20:43
Return for Revision	2024-01-31 20:43
Revised	2024-02-08 19:52
Publication Fee Transferred
Second Decision by Editor	2024-03-19 02:46
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-03-19 11:53
Articles in Press	2024-03-19 11:53
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-04-02 03:16
Publish the Manuscript Online	2024-04-11 08:04

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Obstetrics & Gynecology
Manuscript Type	Case Report
Article Title	Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Guang-Di Zhou and Qin Li
ORCID	Author(s) ORCID Number Guang-Di Zhou http://orcid.org/0000-0003-2009-5011 Qin Li http://orcid.org/0000-0002-8696-039X
Funding Agency and Grant Number
Corresponding Author	Qin Li, MD, Lecturer, Surgeon, Department of Obstetrics and Gynecology, Shanghai Changhai Hospital, No. 168 Changhai Road, Yangpu District, 200433, Shanghai, China. pekingli@163.com
Key Words	Anti-PD-1; Tislelizumab; Ovarian cancer; Relapsed cancer treatment; Immunotherapy; Case report
Core Tip	When chemotherapy, poly adenosine diphosphate ribose polymerase inhibitors, and other treatments are ineffective for relapsed refractory ovarian cancer, anti-programmed death 1 immunotherapy may be the last resort.
Publish Date	2024-04-11 08:04
Citation	Zhou GD, Li Q. Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report. World J Clin Cases 2024; 12(11): 1967-1973
URL	https://www.wjgnet.com/2307-8960/full/v12/i11/1967.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i11.1967

Full Article (PDF)	WJCC-12-1967-with-cover.pdf